Table 2.

Time interval between the onset of COVID-19 and GBS symptoms and laboratory test results

Time Interval (days)		Frequency (%)	Median (± IQR)	Interquartile range		Range (days)
				25th	75th
< 1		2 (3.92)	10.00 ± 12.00	6.00	18.00	0–21
1–10		28 (54.90)
11–20		13 (25.49)
21–30		8 (15.69)
Total		51 (100.00)
Laboratory tests		Patients tested (N)	Status/results	Frequency (%)		GBS subtype
SARS-CoV-2 for COVID-19		51
	Viral Test		Positive	49 (96.08)		All
	Serology Test		Positive	2 (3.92)		AIDP
SARS-CoV-2 in CSF		32	Negative	32 (100)		All
Anti-gang. antibodies		30	Absent	26 (86.67)		All
			GD1b IgG	2 (6.67)		AMAN, MFS
			GM2 IgG/IgM	1 (3.33		GBS*
			GM2 IgM, GD3-IgM, GT1b	1 (3.33)		AIDP
CSF proteins		42	Elevated	34 (80.95)		All
			Normal	8 (19.05)		AIDP, AIDP-MFS, AMSAN
Pleocytosis		37	Absent	37 (100)		All

GBS* GBS not categorized due to absence of nerve conduction studies, Anti-gang antigangliosides